Journal article
Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence.
- Abstract:
-
Recombinant plasmid DNA and attenuated poxviruses are under development as cancer and infectious disease vaccines. We present the results of a phase I clinical trial of recombinant plasmid DNA and modified vaccinia Ankara (MVA), both encoding 7 melanoma tumor antigen cytotoxic T lymphocyte (CTL) epitopes. HLA-A*0201-positive patients with surgically treated melanoma received either a "prime-boost" DNA/MVA or a homologous MVA-only regimen. Ex vivo tetramer analysis, performed at multiple time ...
Expand abstract
- Publication status:
- Published
Actions
Authors
Bibliographic Details
- Journal:
- International journal of cancer. Journal international du cancer
- Volume:
- 113
- Issue:
- 2
- Pages:
- 259-266
- Publication date:
- 2005-01-01
- DOI:
- EISSN:
-
1097-0215
- ISSN:
-
0020-7136
- Source identifiers:
-
32850
Item Description
- Language:
- English
- Keywords:
- Pubs id:
-
pubs:32850
- UUID:
-
uuid:59fc61da-d5a6-404f-97aa-67ad942dbd8b
- Local pid:
- pubs:32850
- Deposit date:
- 2012-12-19
Terms of use
- Copyright date:
- 2005
If you are the owner of this record, you can report an update to it here: Report update to this record